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In this issue, Bonkowsky et al. address the utilization of hematopoietic stem cell transplantation (HSCT) as treatment for rare neurologic conditions for which transplant is not considered standard therapy. They therefore exclude from this analysis severe mucopolysaccharidosis type I (MPS IH, or Hurler syndrome), cerebral adrenoleukodystrophy, metachromatic leukodystrophy, and globoid cell leukodystrophy. Their conclusions include the following: (1) There is a substantial number of patients (91) transplanted between 2000 and 2015 with neurologic disorders that are not considered standard indications for hematopoietic stem cell transplantation; (2) many of these transplants are performed by a relatively small number of institutions, as six centers performed 66 of the identified transplants (72.5%); and (3) transplant is an expensive procedure associated with significant morbidity and mortality, and without sufficient evidence of efficacy, this may constitute an unnecessary burden on the health care system. Based on the above, it is stated that if sufficient benefit has not been demonstrated, transplants should only be performed for nonstandard indications in the setting of a clinical trial, preferentially a prospective, multi-institutional study to maximize patient numbers.
The exploration of transplantation as therapy for lysosomal disorders began in the 1980s, based on the findings of Neufeld's group that accumulation of substrate in cells with lysosomal disease could be eliminated through coculture with wild-type cells. 1 This principle of cellular "cross-correction" led to the hypothesis that establishment of hematopoiesis from an unaffected individual may serve as a continuous and life-long source of enzyme. The first benefit of transplantation was confirmed by Hobbs et al. in 1981 in a child with Hurler syndrome. 2 Since that time, the relative benefits of HSCT have been described for numerous lysosomal disorders, especially the mucopolysaccharidoses and inherited lysosomal leukodystrophies. 7, 12, 19, It is speculated that following transplant there is engraftment of donor-derived microglial cells within the brain of the recipient, serving as a source of enzyme. [57] [58] [59] It is well established that HSCT benefits the cerebral phenotype of adrenoleukodystrophy (ALD) as well. [60] [61] [62] [63] [64] [65] [66] [67] Although achieving some degree of microglial engraftment may prove critical for the stabilization of cerebral adrenoleukodystrophy, the underlying mechanism by which this is achieved appears distinct from the lysosomal disorders. The gene product associated with ALD is bound within the peroxisomal membrane, and there is no evidence of cellular cross-correction analogous to that observed in the lysosomal disorders. Nevertheless, although the biology of the benefit of hematopoietic stem cell transplantation in peroxisomal disease remains elusive, its ability to impact lysosomal disorders with neurologic manifestations are clear. The challenge has been our inability to anticipate which diseases are likely to show a reasonable response. For instance, within the mucopolysaccharidosis disorders, there is generalized agreement as to the neurologic benefits of HSCT for Hurler syndrome sufficient for it to be considered standard of care, 16 whereas the role of hematopoietic stem cell transplantation for mucopolysaccharidosis (MPS) type II (Hunter syndrome) or MPS type III (Sanfilippo) is less clear. [68] [69] [70] [71] [72] [73] [74] [75] [76] Why has transplantation, with the same preparative regimens and graft sources, proved efficacious for MPS IH and less so for MPS II and III? Although animal models may provide some insight, the concordance of these to human phenotypes is less robust than we would like. On this basis, for extremely rare disorders for which experience with hematopoietic stem cell transplantation is limited and the literature is insufficient, it is only through clinical experience that it can be determined whether benefit can be achieved through HSCT, and if so what response may be expected.
If we are then to consider the usefulness of HSCT in a specific setting, one hesitation is the cost. Virtually all would agree that allogeneic transplantation constitutes expensive therapy. The bill for such a transplant in the United States may be well in excess of $1 000 000, although the true cost is generally substantially less. These costs include confirmation of HLA typing of the patient/donor, pretransplant assessments, acquiring the graft, an admission consisting of preparative chemotherapy, infusion of the cell product, and post-transplant supportive care. After discharge, patients are evaluated on an outpatient basis locally for several months, and then return for evaluations for years post-transplantation. Although the resources utilized with cellular therapy such as transplant are substantial, it must be recognized that the medical treatment of patients with rare lysosomal disorders are also extremely high. For instance, the mean age of transplant recipients in the Bonkowsky report was 13 years, and the mean weight of males and females at this age is approximately 45 79, 80 However, hematopoietic stem cell transplantation is generally not offered to patients with attenuated mucopolysaccharidosis type I because of the real risk of morbidity and mortality with transplantation and because neurologic deterioration is not typical for patients with less severe disease. It is thought that the risks of transplant are therefore not justified, as enzyme replacement therapy is available as an alternative and delivery of enzyme to the CNS is not required. Therefore, although costs of therapy are an important consideration, they are not the primary determination.
Establishing efficacy of any therapy in rare disease populations can prove exceedingly challenging. For instance, there are approximately 4 000 000 births within the USA yearly, and a lysosomal disorder such as beta-mannosidosis has an incidence of roughly 1 in 1 000 000. Assuming the diagnosis is established, the age at diagnosis and phenotype would be expected to be variable, and these patients would be spread throughout 50 states. In a setting such as this, it would be extremely difficult to devise and institute a meaningful multi-institutional prospective study to address the benefit of in this condition. What primary outcome would be defined, and subsequently how would the study be powered sufficient to pass statistical review from an IRB? Historically, individual institutions interested in these disorders have offered transplantation using protocols developed globally for metabolic disorders, and have decided internally what disease-specific parameters would be important to monitor. As sufficient information is accumulated, often across decades, a descriptive experience is published, which can prove very meaningful. Occasionally several institutions compile similar retrospective data focused on a specific disorder. However, this is hampered by variation in interinstitutional practices, as one institution may utilize a different chemotherapy regimen and/or methodology of assessment. Even within a given institution practices often change over time in regards to preparative regimens, supportive care, the source of stem cell sources used, etc. Accessing the transplant registries such as the Center for International Blood & Marrow Transplant Research (CIBMTR) and the European Society for Blood and Marrow Transplantation (EBMT) can identify how many patients with a given diagnosis may have been transplanted and when, as well as whether the patient survives. In contrast, the ability to compile disease-specific data sufficient to address motor function and disability, cognition, imaging, etc is extremely difficult.
It is generally agreed that transplantation should be performed in a setting where providers have familiarity with these rare disorders. This increases the likelihood that the disease status can be well characterized before and after HSCT, resulting in meaningful reports of the observations. It is important that the Bonkowsky study found that many of the transplants for nonstandard leukodystrophies were performed by a limited number of institutions. For instance, the group at Minnesota has done more than 500 transplants for patients with inherited metabolic disorders, and published well over 250 articles regarding our findings. Associated with a commitment to these patients and their families is the recognition that optimal care is dependent on the maintenance of a dedicated multidisciplinary group (neurology, neuropsychology, imaging, orthopedics, cardiology, anesthesia, endocrinology, etc) to support transplant efforts. In addition, meaningful assessment of these patients prior to and following transplant is dependent on the familiarity of a variety of subspecialists with the diseases in question. Identifying a limited number of transplant "Centers of Excellence" that have the capacity and commitment to best serve these patients and could prove a path forward in this regard. However, patient access to these centers is likely to be problematic. A high proportion of families will be limited in regard to their ability to travel for care based on either private or state insurance policies. In addition, transplantation requires the relocation of families, often for 4 to 6 months. This is disruptive, a significant stress on the family, and may not be supported by insurance. There are no accepted criteria to define these Centers of Excellence at present. Also, assuming that these are established, their existence would be of limited use if private or state insurance providers do not recognize this role and provide the means for these families to access these centers.
Another key challenge in measuring the benefits of a therapy such as hematopoietic stem cell transplantation is the generation of organizational infrastructure that can serve to define the important questions, establish and unify metrics for assessing disease outcomes and provide a mechanism to acquire and validate data. A network of centers, possibly the aforementioned "Centers of Excellence," could be established that would meet on an ongoing basis to define the compelling questions related to the treatment and the biology of these disorders. The Children's Oncology Group (COG) is an international collaborative research and treatment group that originated in the mid-1950s and was supported by the National Cancer Institute. 81 Prior to the onset of these pediatric oncology cooperative trials, the survival of a child with leukemia was measured in months, but from 1975 to 2006 a 64% reduction in leukemia mortality was achieved. 82 The difficulties in rare, inherited neurologic disorders are clearly distinct from those associated with malignancies, but the lessons learned from the pediatric oncology experience is that disciplined, thoughtful multi-institutional clinical trial design can lead to continuous progress. It could also be argued that monitoring outcomes in cancer may be more binary (relapsed or not, alive or dead, etc) than assessing functional outcomes and recognizing the varied phenotypes and levels of progression important in these rare neurologic disorders. Nevertheless, establishing a meaningful collaborative structure on a national or international basis would be of great benefit in clinical care and research. In my view, we owe it to the affected individuals and families we serve to move the field forward more effectively. 
